Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AWESOME FOX NEWS PICKED UP AYTU FDA APPROVED COVID 19 TEST !
https://www.fox21news.com/health/coronavirus/fda-approves-rapid-coronavirus-test-licensed-by-colorado-company/
AYTU Test is 97.2 percent ACCURATE
announced today that it has received confirmation from the U.S. Food and Drug Administration (FDA) that the company may begin distribution of its Coronavirus Disease 2019 ("COVID-2019") IgG/IgM Rapid Test throughout the United States. The COVID-19 IgG/IgM Rapid Test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care.
AYTU be another news release coming this week then 5 dollars
Aytu BioScience Submits Notice of Commercialization to the FDA, Allowing for Company's Distribution of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test
2020-03-23 08:00 ET - News Release
Commercial Distribution of First 100,000 Tests to Commence Upon Receipt of Inbound Product Shipment
ENGLEWOOD, CO / ACCESSWIRE / March 23, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has received confirmation from the U.S. Food and Drug Administration (FDA) that the company may begin distribution of its Coronavirus Disease 2019 ("COVID-2019") IgG/IgM Rapid Test throughout the United States. The COVID-19 IgG/IgM Rapid Test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care.
Aytu expects delivery of its first shipment of 100,000 tests this week. The Company has been in discussions with healthcare distributors, healthcare institutions, medical practices, and government agencies and is working quickly to begin distribution into the U.S. healthcare supply chain.
Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "We are moving as quickly as we can to bring the COVID-19 IgG/IgM Rapid Test to the U.S. professional medical community. With product now in transit to our warehouse in Colorado we're optimistic that we can have test kits ready for sale in the very near term. In the two short weeks since signing our distribution agreement, we have ordered our first 100,000 tests and have received confirmation from FDA that we may begin distribution. We are optimistic that we're now just days away from placing these COVID-19 test kits into the hands of healthcare professionals."
The COVID-19 IgG/IgM Rapid Test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 126 patient clinical trial and is CE marked.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu recently acquired exclusive U.S. distribution rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 113 patient clinical trial and has received CE marking.
Aytu recently acquired Innovus Pharmaceuticals, a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the company's proprietary Beyond Human® marketing and sales platform.
Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the company's consumer healthcare products.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: market and other conditions, the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering, the regulatory and commercial risks associated with introducing the COVID-19 Rapid Test, effects of the business combination of Aytu and the Commercial Portfolio and the recently completed merger ("Merger") with Innovus Pharmaceuticals, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Commercial Portfolio, the ultimate timing, outcome and results of integrating the operations the Commercial Portfolio and Innovus with Aytu's existing operations, risks relating to gaining market acceptance of our products, obtaining or maintaining reimbursement by third-party payors for our prescription products, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.
Contact for Media and Investors:
James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com
Contact for COVID-19 IgG/IgM Rapid Test-Related Inquiries:
COVID-19@aytubio.com
SOURCE: Aytu BioScience, Inc.
View source version on accesswire.com:
https://www.accesswire.com/582030/Aytu-BioScience-Submits-Notice-of-Commercialization-to-the-FDA-Allowing-for-Companys-Distribution-of-its-2-10-Minute-COVID-19-IgGIgM-Point-of-Care-Rapid-Test
Kits already tested and approved by FDA
SHIPPING TEST KITS this week then start mass production of test kits
AYTU easy 3 dollars tomorrow already has 2 buy recco's on it for 9 and 10 dollars
AYTU huge news today looking for stock to see new YEAR HIGHS this week
AYTU next CODX
Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationwide
2020-03-19 20:23 ET - News Release
Teva will donate 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month
Company Website: http://www.tevapharm.com
TEL AVIV, Israel & PARSIPPANY, N.J. -- (Business Wire)
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the immediate donation of more than 6 million doses of hydroxychloroquine sulfate tablets through wholesalers to hospitals across the U.S. to meet the urgent demand for the medicine as an investigational target to treat COVID-19. The company is also looking at additional ways to address the global need.
“We are committed to helping to supply as many tablets as possible as demand for this treatment accelerates at no cost,” said Brendan O’Grady, Teva Executive Vice President, North America Commercial. “Immediately upon learning of the potential benefit of hyroxychloroquine, Teva began to assess supply and to urgently acquire additional ingredients to make more product while arranging for all of what we had to be distributed immediately.”
Additional production of hydroxychloroquine sulfate tablets is also being assessed and subsequently ramped up with materials that are being sent to Teva from our ingredient supplier. Teva will ship 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month.
Hydroxychloroquine sulfate tablets manufactured by Teva are approved by U.S. Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is not currently approved for use in the treatment of COVID-19, it is currently under investigation for efficacy against the coronavirus and has been requested by US government officials to be made available for use immediately. The Company is also reviewing supply of both hydroxychloroquine and chloroquine globally to determine whether there are additional supply and access opportunities for patients.
Teva is also actively looking across its expansive range of products to determine if the company can help to provide any other products that may be relevant in addressing acute and substantial need during the COVID-19 crisis.
ABOUT TEVA
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.
FORWARD LOOKING STATEMENT
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences are discussed in our Quarterly Reports on Form 10-Q for the first, second and third quarter of 2019 and in our Annual Report on Form 10-K for the year ended December 31, 2018, including in the sections captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005871/en/
Contacts:
IR Contacts
United States
Kevin C. Mannix
(215) 591-8912
Israel
Ran Meir
972 (3) 926-7516
PR Contacts
United States
Kelley Dougherty
973-832-2810
Israel
Yonatan Beker
972 (54) 888 5898
Source: Teva Pharmaceutical Industries Ltd.
Yes all the governments should be handing this drug out but I suspect there not that smart to
Saying the Flu is the same as COVID19 is plain WRONG
"We project that roughly 56% of our state's population -- 25.5 million people -- will be infected with the virus over an eight-week period," he said in a Wednesday letter to Trump asking him to send the USNS Mercy hospital ship to the Port of Los Angeles for use through September 1.
some will wake-up sooner than later
California orders its nearly 40 million residents to stay home to prevent the spread of coronavirus
https://www.cnn.com/2020/03/19/us/california-coronavirus-stay-home-order/index.html
CDC: US coronavirus data shows confirmed cases growing by 500 per day
Cases increasing by 500 per day, CDC report indicates
A person is taken on a stretcher into the United Memorial Medical Center after going through testing for COVID-19 Thursday, March 19, 2020, in Houston. People were lined up in their cars in a line that stretched over two miles to be tested in the drive-thru testing for coronavirus. (AP Photo/David J. Phillip)
A person is taken on a stretcher into the United Memorial Medical Center after going through testing for COVID-19 Thursday, March 19, 2020, in Houston. People were lined up in their cars in a line that stretched over two miles to be tested in the drive-thru testing for coronavirus. (AP Photo/David J. Phillip) (Copyright 2020 The Associated Press. All rights reserved)
A new report from the Centers for Disease Control and Prevention indicates the rate of coronavirus cases is growing by 500 almost daily and those under 50 years old should still be concerned about becoming seriously ill from the coronavirus, despite a majority of deaths in China being patients older than 65 years old.
The report looked at data from cases reported to the CDC in 49 states, the District of Columbia and three U.S. territories from Feb. 12 through March 16.
According to the report, COVID-19 cases in the U.S. indicate that fatality was still highest in persons older than 85, followed by ages 65–84, 55-64 and lastly, those between 20–54 years old. There have not been any reported fatalities among people 19 or younger in the U.S.
A breakdown of all known cases and deaths by the Chinese Center for Disease Control and Prevention showed 14.8% of patients 80 years and older who were infected died as a result. The mortality rate for younger patients in China was much lower.
However, the numbers show the rate of U.S. coronavirus cases requiring hospitalization was more widespread, regardless of age.
On Wednesday, Dr. Deborah Birx, a member of the president’s coronavirus task force, said that health officials are receiving new data out of France and Italy indicating that millennials are being more impacted than previously thought.
Between 14.3 and 20.8% of patients ages 20-44 required hospitalization and 2 to 4% were admitted into intensive care units, according to the CDC. For the next age group, between 44 and 53 years old, between 21 and 28% of patients were hospitalized and up to 10% were in the ICU.
U.S. COVID-19 cases by age requiring hospitalization or ICU stays. (source: CDC)
U.S. COVID-19 cases by age requiring hospitalization or ICU stays. (source: CDC) (WKMG 2020)
It’s also important to note that the CDC based this report on incomplete numbers because its a preliminary report. The authors wrote they were unable to obtain ages for some patients and information about preexisting health conditions.
“Because of these missing data, the percentages of hospitalizations, ICU admissions and deaths were estimated as a range,” according to the report.
Another important takeaway from the U.S. report is the sharp rise in cases since February, including a spike from 500 cases to more than 1,000 in about 48 hours.
U.S. CDC data shows coronavirus cases in the U.S. doubled on March 15, growing by an average of 500 a day. (source: CDC)
U.S. CDC data shows coronavirus cases in the U.S. doubled on March 15, growing by an average of 500 a day. (source: CDC) (WKMG 2020)
“As of March 16, a total of 4,226 COVID-19 cases had been reported in the United States, with reports increasing to 500 or more cases per day beginning March 14,” the report states.
Researchers with the University of Oxford Global Change Data Lab said it’s important not only to look at the death rates from an illness but how quickly the cases doubled.
For example, it took 38 days in China for the cases to double, while it took two days in the U.S. for COVID-19 cases to double, according to data from the European Center for Disease Control and Prevention.
The number of infections in Italy has also risen to more than 41,000
Italy Deaths rose in the last 24 hours to more than 3,400
that's over 8%
On average, seasonal flu strains kill about 0.1 percent of people who become infected.
The 1918 flu had an unusually high fatality rate, around 2 percent. Because it was so contagious, that flu killed tens of millions of people.
Early estimates of the coronavirus death rate from China were about 2 percent
the numbers don't lie
everybody can believe whatever they like that's there opinion
PS Better hope this drug works CHLOROQUINE
maybe you will get it at some point but carry on
“This is a dangerous virus.”
Edmonton man becomes first to die from COVID-19 in Alberta Alberta’s chief medical officer has reported the first person to die in that province from COVID-19.
Dr. Deena Hinshaw said a patient from the Edmonton region died after being in the intensive-care unit since last Thursday. The patient, a man in his 60s, had underlying health conditions, said Dr. Hinshaw.
“This is extremely sad news and all of us involved in Alberta’s COVID response feel this very deeply," said Dr. Hinshaw, who added that fatalities are nonetheless expected.
“This is a dangerous virus.”
https://www.theglobeandmail.com/canada/article-the-latest-on-the-coronavirus-ontario-records-second-pandemic-death/
$AGNPF $AGN Three companies using solid science to fight the COVID-19 virus
https://equity.guru/2020/03/16/three-companies-using-solid-science-fight-covid-19-virus/
$AGNPF $AGN Three companies using solid science to fight the COVID-19 virus
https://equity.guru/2020/03/16/three-companies-using-solid-science-fight-covid-19-virus/
Why is everything in the world shutting down ? For Fun?
Take this a little more serious cause its very serious
But each to there own
Coronavirus has now spread to all 50 states, US death toll passes 100
Coronavirus has now spread to all 50 states, US death toll passes 100 https://t.co/r83qxHPqoO
— CNBC (@CNBC) March 17, 2020
Coronavirus has now spread to all 50 states, US death toll passes 100
Coronavirus has now spread to all 50 states, US death toll passes 100 https://t.co/r83qxHPqoO
— CNBC (@CNBC) March 17, 2020
AGN or AGNPF --The World Health Organization (WHO) has released its COVID-19 R&D roadmap, highlighting the gaps in knowledge about the virus and setting out priorities for research. The organization is now calling on groups around the world to use the document – drawn up by 400 experts – to coordinate their efforts. The research roadmap is backed by a core set of protocols WHO has developed outlining how clinical studies should be designed and how data are collected, to ensure it is possible to compare and pool data from multiple clinical studies.
The Gates Foundation and Wellcome Trust have joined forces with financial services specialist Mastercard in establishing a $125 million seed fund to accelerate development of drugs to treat COVID -19. The COVID-19 Therapeutics Accelerator aims to play a catalytic role by speeding up evaluation of new and repurposed drugs and biologics to treat the novel coronavirus in the near term, and other viral pathogens in the longer term.
https://www.bioworld.com/articles/433724-week-in-review-for-march-9-13-2020
AGN or AGNPF --The World Health Organization (WHO) has released its COVID-19 R&D roadmap, highlighting the gaps in knowledge about the virus and setting out priorities for research. The organization is now calling on groups around the world to use the document – drawn up by 400 experts – to coordinate their efforts. The research roadmap is backed by a core set of protocols WHO has developed outlining how clinical studies should be designed and how data are collected, to ensure it is possible to compare and pool data from multiple clinical studies.
The Gates Foundation and Wellcome Trust have joined forces with financial services specialist Mastercard in establishing a $125 million seed fund to accelerate development of drugs to treat COVID -19. The COVID-19 Therapeutics Accelerator aims to play a catalytic role by speeding up evaluation of new and repurposed drugs and biologics to treat the novel coronavirus in the near term, and other viral pathogens in the longer term.
https://www.bioworld.com/articles/433724-week-in-review-for-march-9-13-2020
03-11 08:00 ET - News Release
ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu's common stock (or common stock equivalent), at a purchase price of $1.15 per share
aytu could close anywhere could be back to 3 buks or 1 buk
all gambling
1.62 to 1.63 I show last 1.63
halting stock to get it to trade lower and lower
crooks are working it
buy the dip before close it they try to crash it
$AGNPF $AGN Boom Algernon Scales up Manufacturing of NP-120 (Ifenprodil) to Prepare for Coronavirus and Acute Lung Injury US Clinical Trials
http://www.globenewswire.com/news-release/2020/03/09/1997174/0/en/Algernon-Scales-up-Manufacturing-of-NP-120-Ifenprodil-to-Prepare-for-Coronavirus-and-Acute-Lung-Injury-US-Clinical-Trials.html
$AGNPF $AGN Boom Algernon Scales up Manufacturing of NP-120 (Ifenprodil) to Prepare for Coronavirus and Acute Lung Injury US Clinical Trials
http://www.globenewswire.com/news-release/2020/03/09/1997174/0/en/Algernon-Scales-up-Manufacturing-of-NP-120-Ifenprodil-to-Prepare-for-Coronavirus-and-Acute-Lung-Injury-US-Clinical-Trials.html
ORIGINAL: Algernon Scales up Manufacturing of NP-120 (Ifenprodil) to Prepare for Coronavirus and Acute Lung Injury US Clinical Trials
2020-03-09 08:45 ET - News Release
AGN AGNPF Close 2020-03-06 C$ 0.15
VANCOUVER, British Columbia, March 09, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has made the decision to begin production of NP-120 (Ifenprodil) with a new injectable and long acting oral release formulation, in order to be prepared for new US clinical trials for COVID-19 (coronavirus) and acute lung injury (ALI).
The decision was made after a recent independent study found that Ifenprodil significantly reduced ALI and improved survivability in an animal study with Asian H5N1 infected mice by 40%. Asian H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate. This compelling data, generated via a genome wide RNAi interference approach, that lead the investigators to the identification of Ifenprodil, an NMDA receptor antagonist, has been a major contributing factor in the Company’s decision.
The Company is in negotiations with a number of manufacturers and will be announcing more details on its decision shortly.
“The Company believes strongly in the potential of Ifenprodil to treat patients who have a severe acute lung injury, including people who have various forms of respiratory infections including COVID-19 (coronavirus) and influenza,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
Algernon has filed new intellectual property rights for NP-120 (Ifenprodil) for the treatment of respiratory diseases.
About NP-120 (Ifenprodil)
NP-120 (Ifenprodil) is an N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil also exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. Although the anti-fibrotic activity of Ifenprodil in IPF is not known, recent studies have suggested a link between both receptors and pathways associated with fibrosis.
Glutamate (Glu) is the main excitatory neurotransmitter which acts on glutamate receptors in the central nervous system (CNS) but overactivation of these receptors can cause several damages to neural cells including death. Recent studies show that the glutamate agonist N-methyl-d-aspartate (NMDA) can trigger acute lung injury (ALI). ALI is a direct and indirect injury to alveolar epithelial cells and capillary endothelial cell, causing diffuse pulmonary interstitial and alveolar edema and acute hypoxic respiration failure. ALI is characterized by reduced lung volume and compliance, and imbalance of the ventilation/perfusion ratio, inducing hypoxemia and respiratory distress and its severe stage (oxygen index <200) known as acute respiratory distress syndrome (ARDS). (1) Furthermore, pathological findings show that 64% of ARDS patients may have pulmonary fibrosis during convalescence (2).
NP-120 (Ifenprodil - brand name Cerocal) was initially developed by Sanofi in the 1990s in the French and Japanese markets for the treatment of circulatory disorders. The drug is genericized and sold in Japan.
About Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), and chronic cough.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.cominvestors@algernonpharmaceuticals.comwww.algernonpharmaceuticals.com.
ORIGINAL: Algernon Scales up Manufacturing of NP-120 (Ifenprodil) to Prepare for Coronavirus and Acute Lung Injury US Clinical Trials
2020-03-09 08:45 ET - News Release
AGN AGNPF Close 2020-03-06 C$ 0.15
VANCOUVER, British Columbia, March 09, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has made the decision to begin production of NP-120 (Ifenprodil) with a new injectable and long acting oral release formulation, in order to be prepared for new US clinical trials for COVID-19 (coronavirus) and acute lung injury (ALI).
The decision was made after a recent independent study found that Ifenprodil significantly reduced ALI and improved survivability in an animal study with Asian H5N1 infected mice by 40%. Asian H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate. This compelling data, generated via a genome wide RNAi interference approach, that lead the investigators to the identification of Ifenprodil, an NMDA receptor antagonist, has been a major contributing factor in the Company’s decision.
The Company is in negotiations with a number of manufacturers and will be announcing more details on its decision shortly.
“The Company believes strongly in the potential of Ifenprodil to treat patients who have a severe acute lung injury, including people who have various forms of respiratory infections including COVID-19 (coronavirus) and influenza,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
Algernon has filed new intellectual property rights for NP-120 (Ifenprodil) for the treatment of respiratory diseases.
About NP-120 (Ifenprodil)
NP-120 (Ifenprodil) is an N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil also exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. Although the anti-fibrotic activity of Ifenprodil in IPF is not known, recent studies have suggested a link between both receptors and pathways associated with fibrosis.
Glutamate (Glu) is the main excitatory neurotransmitter which acts on glutamate receptors in the central nervous system (CNS) but overactivation of these receptors can cause several damages to neural cells including death. Recent studies show that the glutamate agonist N-methyl-d-aspartate (NMDA) can trigger acute lung injury (ALI). ALI is a direct and indirect injury to alveolar epithelial cells and capillary endothelial cell, causing diffuse pulmonary interstitial and alveolar edema and acute hypoxic respiration failure. ALI is characterized by reduced lung volume and compliance, and imbalance of the ventilation/perfusion ratio, inducing hypoxemia and respiratory distress and its severe stage (oxygen index <200) known as acute respiratory distress syndrome (ARDS). (1) Furthermore, pathological findings show that 64% of ARDS patients may have pulmonary fibrosis during convalescence (2).
NP-120 (Ifenprodil - brand name Cerocal) was initially developed by Sanofi in the 1990s in the French and Japanese markets for the treatment of circulatory disorders. The drug is genericized and sold in Japan.
About Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), and chronic cough.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.cominvestors@algernonpharmaceuticals.comwww.algernonpharmaceuticals.com.
AGW Last price 0.143 in Frankfurt = AGN .22 cents Canadian
AGNPF
AGW Last price 0.143 in Frankfurt = AGN .22 cents Canadian
AGNPF
the board is all yours I won't be back find your own info
READ CONNECTION with $AGNPF $AGN COVID-19, (coronavirus)
The autopsy results Liu shared inspired me a lot. Based on the results, I think the most important thing now is to take measures at an early stage of the disease to protect patients’ lungs from irreversible fibrosis,”
https://www.news.com.au/lifestyle/health/health-problems/chinese-doctors-say-coronavirus-like-a-combination-of-sars-and-aids-can-cause-irreversible-lung-damage/news-story/f58f19c5eeae99b845c54e2d2b9305ca
__________________________________________________________________
“If we see a similar response in coronavirus patients as seen in the H5N1 animal study, a far more lethal form of influenza, we believe that patient outcomes should be significantly improved”, said Christopher J. Moreau, CEO of Algernon.
Algernon welcomes contact from health organizations and physicians globally to learn more about NP-120 (Ifenprodil).
Management’s belief that NP-120 (Ifenprodil) is a possible treatment for COVID-19, (coronavirus) is based on historic animal studies and not on human trials.
http://www.globenewswire.com/news-release/2020/03/06/1996671/0/en/Algernon-Announces-Availability-of-its-NP-120-Ifenprodil-Drug-for-Compassionate-Use-for-Coronavirus.html